Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial

Autor: Javier Cortes, Alison L. Hannah, Mary Tagliaferri, Hope S. Rugo, Ahmad Awada, David Potter, Chris Twelves, Edith A. Perez, Carol Zhao, Jin Seok Ahn, Ute Hoch, Patricia Gómez-Pardo, Seock–Ah –A Im, Audrey Mailliez, Lee S. Schwartzberg, Joyce O'Shaughnessy, Véronique Diéras, Denise A. Yardley, Alvaro Moreno-Aspitia
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Cancer Research
Lung Neoplasms
Health Status
Docetaxel
Disease
Deoxycytidine
Polyethylene Glycols
0302 clinical medicine
Quality of life
Sleep Initiation and Maintenance Disorders
Activities of Daily Living
Fatigue
Aged
80 and over
Brain Neoplasms
Liver Neoplasms
Nausea
Vinorelbine
Cancer Pain
Ketones
Middle Aged
Metastatic breast cancer
humanities
Anorexia
Reproductive Health
030220 oncology & carcinogenesis
Advanced breast cancer
Female
Taxoids
Etirinotecan pegol
Adult
medicine.medical_specialty
Paclitaxel
Anthracycline
Vomiting
NKTR-102
Antineoplastic Agents
Bone Neoplasms
Breast Neoplasms
Vinblastine
Heterocyclic Compounds
4 or More Rings
03 medical and health sciences
Breast cancer
Albumins
Internal medicine
Body Image
medicine
Humans
Furans
Aged
Taxane
business.industry
Cancer
medicine.disease
Gemcitabine
Cancérologie
Dyspnea
030104 developmental biology
Epothilones
Quality of Life
Physical therapy
business
Zdroj: European journal of cancer, 76
ISSN: 0149-2101
0959-8049
Popis: Background Health-related quality of life (HRQoL) enhances understanding of treatment effects that impact clinical decision-making. Although the primary end-point was not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established etirinotecan pegol, a long-acting topoisomerase-1 (TOP1) inhibitor, as a promising therapeutic for patients with advanced/metastatic breast cancer (MBC) achieving clinically meaningful benefits in median overall survival (OS) for patients with stable brain metastases, with liver metastases or ≥ 2 sites of metastatic disease compared to treatment of physician's choice (TPC). Reported herein are the findings from the preplanned secondary end-point of HRQoL. Patients and methods HRQoL, assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) (version 3.0) supplemented by the breast cancer-specific Quality of Life Questionnaire (QLQ-BR23), was evaluated post randomisation in 733 of 852 patients with either anthracycline-, taxane- and capecitabine-pretreated locally recurrent or MBC randomised to etirinotecan pegol (n = 378; 145 mg/m2 every 3 weeks (q3wk)) or single-agent TPC (n = 355). Patients completed assessments at screening, every 8 weeks (q8wk) during treatment, and end-of-treatment. Changes from baseline were analysed, and the proportions of patients achieving differences (≥5 points) in HRQoL scores were compared. Results Differences were seen favouring etirinotecan pegol up to 32 weeks for global health status (GHS) and physical functioning scales (P
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: